Virus – induced Asthma Treatment Market- Detailed Analysis of Current Industry FPosted by sachi kaushik on March 22nd, 2021 The onset of an asthma attack due to a respiratory tract infection is considered as virus-induced asthma. This includes viruses associated with the common cold and flu. It is observed that 50% of all acute asthma attacks are triggered by a respiratory virus. As opposed to poorly controlled asthma—in which attacks occur due to inadequate drug treatment or adherence)—viral-induced asthma can occur even in people with excellent asthma control. The global virus-induced asthma treatment market will rise during the forecast period, with the growing prevalence of asthma and rising approvals for the therapies across the globe. To remain ‘ahead’ of your competitors, request for a sample @ https://www.factmr.com/connectus/sample?flag=S&rep_id=5663 The virus-induced asthma treatment market is expected to be driven by increase in product approvals by the FDA and other regulatory bodies, Furthermore, the rising prevalence of asthma, and strategic approaches such as collaborations & partnerships by market players is driving the market growth. Also, rise in the opportunities for market players to expand their geographical presence in emerging countries will fuel the growth of the global virus-induced asthma treatment market. Key Segments of Virus-induced Asthma Treatment Market Covered in the Report Based on treatment, the global virus-induced asthma treatment market has been segmented as
Based on route of administration, the global virus-induced asthma treatment market has been segmented as
Based on distribution channel, the global virus-induced asthma treatment market has been segmented as
Based on the region, the global virus-induced asthma treatment market has been segmented as
Competitive Landscape Key players such as
Why Long-term Control Medications dominating Virus-induced Asthma Treatment Market? Asthma is considered to be a chronic disorder, thus the primary treatment for such disorders is often term control medications. Hence, long-term control medications dominated the virus-induced asthma treatment market in 2020. Some of the key drug classes of long-term control medications is leukotriene modifiers, anticholinergics, immunomodulators, and inhaled and combined corticosteroids. How Increasing R&D to Augment Virus-induced Asthma Treatment Market Growth? The strong and robust R&D being undertaken by major players for developing advanced therapeutics for virus-induced asthma treatment market is the key trend in the market. Since, asthma is a chronic disorder, that affects a huge number of population every year, a number of pharmaceutical companies are involved in the development of drugs for asthma. This is due to the presence of several strong pipeline candidates for virus-induced asthma treatment in various stages of clinical trials. For instance, In September, 2019, Novartis announced positive results from the phase III IRIDIUM study of inhaled combination QVM149 in patients diagnosed with uncontrolled asthma. This drug is being observed to be very effective in treating patients by better controlling their virus-induced asthma symptoms. This leads to better improvements in the functioning of lungs. These type of positive clinical developments is likely to further propel the virus-induced asthma treatment market growth. What strategies are the Key Players adopting for Increasing their Market Share in the Virus-induced Asthma Treatment Market? Key players are involved in mergers and acquisition to strengthen their market position, owing to increasing competition frequent innovations are taking place in the market. The virus-induced asthma treatment market is a monopolistic market, with the presence of numerous companies. In the market, two companies AstraZeneca plc and GlaxoSmithKline plc are dominating the market with their strong product portfolio and presence across the world. However, there are other prominent players in the market such as Merck and Teva. This is projected to positively impact the market during the forecast period. Major companies are focusing on enhancing their marketing strategies, reduction in cost, expanding geographical presence and increasing sales networking in order to gain maximum market share. Various macroeconomic factors, market trends and technological advancements play a vital role in the growth of global virus-induced asthma treatment market. Why is the U.S. a Big Market for Virus-induced Asthma Treatment? In recent years, the prevalence trends of asthma indicate a growth in the number of new diagnoses. In 2010, 2011 and 2016 saw the highest prevalence of asthma diagnoses in the U.S. Medical care costs for respiratory disorders have also shown to be increasing in recent years. Patients face higher medical costs and indirect costs of missed workdays and illness time without proper treatment. Furthermore, the presence of major players in the country and robust R&D are likely to increase the market in the region. U.S. is the most dominating country in the market and is expected to continue during the forecast period. Why India dominating Asia Pacific in Virus-induced Asthma Treatment Market? The rising prevalence of respiratory disorder and rising geriatric population in the country is likely to drive the India virus-induced asthma treatment market. Also, the higher number of medical tourism activities in the country drives the market. India is a developing country with many cities undergoing rapid urbanization and increased awareness; hence, it is expected to show a significant rise in the prevalence of asthma and other allergies. The burden of asthma morbidity is higher in developed countries and is increasing in developing countries. This is likely to create a huge opportunity for the virus-induced asthma treatment market to expand during the forecast period. The Report Covers Exhaustive Analysis on:
Regional Analysis Includes
About Us: Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner. Contact: US Sales Office: Corporate Headquarter: Like it? Share it! More by this author |